Preclinical assessment of the potential utility of oxytocin and a novel oxytocin agonist for the treatment of substance use disorders and social dysfunction [ 2015 - ]

Research Grant

Researchers: Dr Michael Bowen (Principal investigator)

Brief description Recent work has highlighted the utility of stimulating the brain oxytocin (OT) system in the treatment of numerous psychiatric disorders, in particular substance use disorders and social disorders (e.g. autism). I will focus on the continuation of two interrelated projects during my Fellowship: (1) preclinical exploration of OT as a novel treatment for alcohol use disorders; and (2) further developing our novel non-peptide OT agonist (SOC-1), which has profound pro-social effects.

Funding Amount $309,436.00

Funding Scheme Early Career Fellowships

Notes Peter Doherty Biomedical ECF